Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
List view / Grid view
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
Patients who received tocilizumab in the retrospective, single-centre study were 45 percent less like to die and more likely to come off ventilation within 28 days.
Clinical trial testing a live biotherapeutic in hospitalised COVID-19 patients suggests the bacteriotherapy could be promising.
According to research, the rise in demand for high-quality cannabis will also drive growth in the cannabis testing market, where new technologies are needed to overcome current limitations.
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
Integrated electronic SOPs and maps are “all in the box” to help reduce errors.
Two investigational SARS-CoV-2 vaccine candidates, BNT162b1 and BNT162b2, currently in clinical trials have been granted Fast Track designation by the FDA.
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
Gilead reveals the novel inhaled formulation of remdesivir entered Phase I trials to establish if it could be used to treat mild to moderate COVID-19.
Q Biomed entered into a Named Patient Programme distribution agreement for Strontium89, a non-opioid metastatic bone cancer pain drug.
The agency’s opinion will require companies to take measures to reduce nitrosamine impurities in medicines and carry out and action the results of risk assessments.
A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both a prophylactic and a treatment have begun in US and some South American locations.
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
Scientists unveil their model, which other researchers can use to test the injectability of their drug delivering microparticle designs in silico.